132194-23-1 Usage
Description
(2S)-5α-(2-Amino-6-iodo-9H-purine-9-yl)tetrahydrofuran-2α-methanol is a unique chemical compound characterized by a tetrahydrofuran ring with a 2α-methanol substitution and a purine derivative attached. The purine derivative features an amino group and an iodine atom at specific positions, which contribute to the compound's distinctive structure and reactivity. (2S)-5α-(2-Amino-6-iodo-9H-purine-9-yl)tetrahydrofuran-2α-methanol holds potential in the realm of medicinal chemistry, particularly for the development of pharmaceutical drugs that target specific biological pathways or interactions involving purine derivatives. Further research and experimentation are required to ascertain its precise properties and potential applications.
Uses
Used in Medicinal Chemistry:
(2S)-5α-(2-Amino-6-iodo-9H-purine-9-yl)tetrahydrofuran-2α-methanol is utilized as a key component in the development of pharmaceutical drugs, specifically for targeting biological pathways or interactions that involve purine derivatives. Its unique structure, including the tetrahydrofuran ring and the iodine atom, may offer novel therapeutic opportunities in medicine.
Used in Drug Development:
In the pharmaceutical industry, (2S)-5α-(2-Amino-6-iodo-9H-purine-9-yl)tetrahydrofuran-2α-methanol is employed as a building block for creating new drug candidates. Its potential to interact with specific biological targets makes it a valuable asset in the design and synthesis of innovative medications aimed at treating various diseases and conditions.
Used in Research and Experimentation:
(2S)-5α-(2-Amino-6-iodo-9H-purine-9-yl)tetrahydrofuran-2α-methanol serves as a subject of interest in scientific research and experimentation. Its unique chemical properties and potential applications in medicinal chemistry make it a promising candidate for further study, with the aim of uncovering its full potential and understanding its interactions with biological systems.
Check Digit Verification of cas no
The CAS Registry Mumber 132194-23-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,1,9 and 4 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 132194-23:
(8*1)+(7*3)+(6*2)+(5*1)+(4*9)+(3*4)+(2*2)+(1*3)=101
101 % 10 = 1
So 132194-23-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H12IN5O2/c11-8-7-9(15-10(12)14-8)16(4-13-7)6-2-1-5(3-17)18-6/h4-6,17H,1-3H2,(H2,12,14,15)/t5-,6+/m0/s1
132194-23-1Relevant articles and documents
Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides
Murakami,Shirasaka,Yoshioka,Kojima,Aoki,Ford Jr.,Driscoll,Kelley,Mitsuya
, p. 1606 - 1612 (2007/10/02)
A series of 6-substituted 2',3'-dideoxypurine ribofuranosides (ddP) was enzymatically synthesized with live E. coli in an effort to enhance the lipophilicity of this class of anti-human immunodeficiency virus (HIV) compounds and thereby facilitate drug delivery into the central nervous system. All 6-halo-substituted ddPs were substantially more lipophilic, as defined by their octanol-water partition coefficient (P), than their nonhalogenated congeners 2',3'-dideoxyinosine (ddI) or 2',3'-dideoxyguanosine (ddG). For this class of compounds, log P's ranged from +0.5 to -1.2 in the following order: 6-iodo, 2-amino-6-iodo > 6-bromo, 2-amino-6-bromo > 6-chloro, 2-amino-6-chloro > 6-fluoro, 2-amino-6-fluoro >> ddG > ddI. These compounds were evaluated in vitro for ability to suppress the infectivity, replication, and cytopathic effect of HIV. 2-Amino-6-fluoro-, 2-amino-6-chloro-, and 6-fluoro-ddP exhibited a potent activity against HIV comparable to that of ddI or ddG and completely blocked the infectivity of HIV without affecting the growth of target cells. The comparative order of in vitro anti-HIV activity was 2-amino-6-fluoro, 2-amino-6-chloro, 6-fluoro > 2-amino-6-bromo > 2-amino-6-iodo, 6-chloro > 6-bromo > 6-iodo. These compounds also exhibited potent in vitro activity against HIV-2 and 3'-azido-3'-deoxythymidine-resistant HIV-1 variants. All 2-amino-6-halo-ddPs and 6-halo-ddPs were substrates for adenosine deaminase (ADA) and were converted to ddG or ddI, respectively. In the presence of the potent ADA inhibitor 2'-deoxycoformycin, 6-halo-substituted ddPs failed to exert an in vitro antiretroviral effect. These dideoxypurine nucleoside analogues represent a new class of lipophilic prodrugs of ddG and ddI that possess the potential for more effective therapy of HIV-induced neurologic disorders.